GHR Foundation
  • Impact Areas
    • Global Engagement >
      • Children in Families
      • Prepare The Future
      • Programs in Transition >
        • BridgeBuilder >
          • Overview
          • 2017 Top Ideas >
            • Peace Direct
            • BioCarbon Engineering
            • LIFT Chicago
            • Local Youth Corner Cameroon
            • NaTakallam
          • 2018 Top Ideas >
            • This is My Backyard
            • Found in Translation
            • Producers Direct
            • War Child Canada
            • My Choices Foundation
          • 2019 Top Ideas >
            • Top Manta
            • Five One Labs
            • SAMA for All
            • Talent Beyond Boundaries
            • FaithAction
        • Inter-Religious Action
        • Sister Support
    • Catholic Education
    • Twin Cities Racial Equity (TCRE)
    • Alzheimer's Initiative
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • FAQs
    • Grants & Financials
  • Contact

Highlights from AAIC 2022

8/9/2022

0 Comments

 
An air of optimism marked the Alzheimer’s Association International Conference (AAIC) in San Diego last week, as over 9,000 scientists joined in-person and virtually to share research discoveries, connect with their peers and learn from others. Several presenters highlighted the exciting potential of recent scientific developments, considered almost impossible to conceive of five or ten years ago. Today, the scientific community can completely remove amyloid plaque in the brain as measured by PET scans – the buildup of which is considered a precursor to Alzheimer’s Disease. New blood biomarkers offer greater understanding and ability to detect disease, without the cost and invasiveness of alternative testing procedures. Finally, prevention therapy offers the potential to treat Alzheimer’s patients ten to twenty years before the onset of symptoms.

The Alzheimer’s Association is a valued partner in our shared journey to find a way to prevent Alzheimer’s Disease and related dementias. Together, we have provided key philanthropic support to prevention trials in early onset families and in the general population. 
​

You can review the news highlights from AAIC and press releases to learn more about the exciting discoveries shared at AAIC 2022.

0 Comments

Pioneering Alzheimer’s Prevention Study Starts Enrollment

8/29/2016

 
Picture
GHR’s Health initiative partners with organizations using innovative trials to pursue the prevention of Alzheimer’s disease. One such trial is the Alzheimer’s Prevention Initiative (API) Generation Study which recently began enrollment in high-risk older adults to validate the use of genetic screening and identify an effective approach to prevent the disease.

Led by Dr. Eric Reiman and Dr. Pierre Tariot of Banner Alzheimer’s Institute (BAI), this pioneering multi-site prevention study is working to determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of Alzheimer’s symptoms in people at a high genetic risk of developing the disease. The study will involve more than 1,300 cognitively healthy adults, age 60 to 75, who have inherited a copy of the e4 type of the apolipoprotein (APOE) gene from each parent. Roughly one in four people carry a single copy of the gene, which is strongly linked to late-onset Alzheimer’s.

The Generation Study is part of the API, an international collaborative led by BAI to accelerate the evaluation of promising treatments. The study is sponsored by Swiss pharmaceutical company Novartis and Thousand Oaks, Calif.-based biotechnology company Amgen in collaboration with BAI, with funding from the National Institute on Aging—part of the National Institutes of Health—as well as GHR, Alzheimer’s Association, Fidelity Biosciences Research Institute and Banner Alzheimer’s Foundation.

To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us.

GHR receives the Stone Award for Alzheimer’s Research

8/18/2015

 
Picture
GHR Foundation’s Health Initiative is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on a game-changing undertaking—the prevention of Alzheimer’s disease. Recently, GHR Foundation was awarded the Jerome H. Stone Philanthropy Award for Alzheimer’s Research for its philanthropic efforts to support Alzheimer’s disease prevention research. The award was also presented to the MetLife Foundation, which works with experts to assist low-income individuals facing Alzheimer’s.

The recognition was presented at the Annual Alzheimer’s Association International Conference in memory of Alzheimer’s Association founder Jerome Stone, who passed away earlier this year. Fred Miller accepted the award on behalf of the Foundation at the opening plenary session, attended by more than 4,000 global researchers, donors and advocates. This year’s Alzheimer’s Conference also saw the release of promising new prevention research results.  To see a summary of news from the Conference, read the Alzheimer’s Association news release.

We are happy to accept this recognition as an innovative partner in the fight against Alzheimer’s. The Stone Award strengthens GHR’s credibility as we cultivate important public- and private-sector partners. To learn more about how GHR’s Health Initiative, contact us.

New Grant to Support Launch of APOE4 Alzheimer’s Trial

6/1/2015

 
GHR Foundation is joining forces with philanthropic and industry partners to fund groundbreaking Alzheimer’s prevention research. One such partnership is the APOE trial, a prevention study that will launch by early 2016 and last five years. GHR has partnered with the Alzheimer’s Association and Fidelity Biosciences Research Initiative to provide $10 million in new research funding to support the study.

The API APOE4 trial, conducted by the Banner Alzheimer’s Institute in Phoenix, Arizona, is focused on how two new therapies may prevent or delay the development of Alzheimer’s symptoms in a population known to be at high risk for the disease because of their age and genetic status. The trial will test two different potential approaches to see if one or both can prevent the development of memory and thinking symptoms of Alzheimer’s.

The new funding will support three aspects of the API APOE4 trial, including the expansion of the Alzheimer’s Prevention Registry, the evaluation of two remote genetic counseling approaches and new scans including Tau PET imaging, amyloid PET imaging and FDG-PET imaging. If successful, the trial will not only to evaluate investigational prevention therapies, but will help find faster ways to evaluate promising prevention therapies in the future.

To learn more about how the Foundation is targeting funding to improve some of the largest research efforts in the field, contact us.
Picture

Alzheimer's Research Making Headlines

4/6/2015

1 Comment

 
Picture
From People Magazine: Alzheimer’s patient Sonia Cardona and her caregiver and daughter Daisy Duarte.
The fight against Alzheimer’s disease is making headlines. Fueled by research advances and popular culture attention, GHR-funded projects targeting Alzheimer's prevention are building public awareness. Grants making headlines include:
  • DIAN-TU Study: GHR is one of the funders of the Washington University study to quickly evaluate potential prevention treatments among people most likely to develop the disease. Trial participant Daisy Duarte was recently profiled in People Magazine. This article, along with Oscar attention for “Still Alice”—a film about a woman with early-onset Alzheimer’s—is helping to bring prevention research into the public spotlight.
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Study (A4): GHR is also contributing to the A4 Harvard study that is designed to identify and treat patients in the earliest stages of Alzheimer's, before memory loss begins. Recently, A4 researchers conducted the first scans in a clinical trial for the presence of the protein tau, which forms toxic tangles of nerve fibers associated with Alzheimer's. The addition of tau imaging into this trial was directly funded by GHR and is our primary contribution to the study. The breakthrough scans will enable researchers to see the effects of an experimental drug on both amyloid plaques and tau tangles for the first time, potentially leading to more effective prevention and treatments.

Recent headlines document important milestones in the fight against Alzheimer's. GHR supports research that inspires hope among those impacted by the disease and advances opportunities for real results. For more information, contact us.
1 Comment

GHR-Funded Alzheimer’s Study Focuses on Physician Outreach

10/13/2014

0 Comments

 
Picture
The journal Clinics in Geriatric Medicine recently published the results of GHR-funded physician outreach efforts by the Minnesota/North Dakota Chapter of the Alzheimer’s Association. Published as part of a larger article titled, “Developing Dementia-Capable Health Care Systems,” the piece highlights the importance of engaging community-based organizations like the Alzheimer’s Association in connecting patients with caregivers. 

The research shows how community-based organizations reinforce services commonly provided by social workers. These services range from providing information for physicians regarding caregiver education to referring community services. The Minnesota/North Dakota Chapter of the Alzheimer’s Association was specifically highlighted, due to its newly-developed network of providers and clinics, which made an important step in establishing dementia-capable health care by increasing the occurrence of direct contact between patients and physicians.

GHR supports innovative new approaches to address the impact of Alzheimer’s disease.  Learn more about our grant making today.
0 Comments

Fight Against Alzheimer’s Focuses on Prevention

8/12/2014

0 Comments

 
Picture
Photo credit: The Mayo Clinic
GHR Foundation attended the Alzheimer’s Association International Conference. As an important platform to present research and trend information, the forum saw global news coverage on potential new diagnostics, findings related to lifestyle and international rates of prevalence. 

A Wall Street Journal piece covering the conference entitled “Alzheimer's Disease Fight Focuses on Preventive Treatment” reinforces GHR’s focus on funding effective prevention therapies. It notes that “greater ability to measure the progression of the disease in the brain through the use of biological markers, such as the imaging of disease-related proteins, has made it easier to detect the subtle and slow progression of the disease...”

To advance our Alzheimer’s strategy, GHR’s Alzheimer’s advisory council convened a strategic meeting at the conference to discuss the impact of research, potential collaboration and next steps. The Foundation is pleased to be partnering with so many public and private sectors leaders in the fight against Alzheimer’s disease.
0 Comments

    Categories

    All
    A4
    Alzheimer's
    Alzheimer's Association
    BridgeBuilder
    C2N
    Catholic Schools
    Children In Families
    COVID-19
    Develop Diagnostics
    DIAN Primary Prevention
    DIAN-TU
    Education
    Global Development
    Higher Education
    Inter-Religious Action
    La Jolla Institute
    Mayo Clinic
    Mayo Clinic Study Of Aging
    NIH-NIA
    Observational Studies
    Prepare The Future
    Prevention Trials
    Sister Support
    Twin Cities Racial Equity

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    April 2019
    March 2019
    December 2018
    November 2018
    October 2018
    September 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    August 2017
    July 2017
    May 2017
    April 2017
    March 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    August 2014
    July 2014
    May 2014
    April 2014
    March 2014
    October 2013
    December 2012

    RSS Feed

CONNECT WITH US

IMPACT AREAS  |  NEWS  |  ABOUT  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2023 GHR FOUNDATION
All Rights Reserved.